EXSCIENTIA
4.8.2021 10:02:12 CEST | Business Wire | Press release
Exscientia today announced the opening of a 21,000 square foot expansion of its facilities at Oxford Science Park, increasing capacity for its technology teams as well as significantly expanding its laboratory-based experimental capabilities in structural biology, biophysics and high-content pharmacology.
In parallel, Exscientia is building a new 26,000 square foot robotic laboratory at nearby Milton Park, Oxfordshire focused on the automation of chemistry and biology to accelerate drug discovery. This will take Exscientia towards its goal of drugs designed AI, made by robot.
“Exscientia has grown significantly in 2021, driven by new partnerships with leading pharma and biotech companies, as well as by our in-house drug discovery work. Our pipeline includes more than 25 active research programs across therapeutic areas, with a focus on immunology and oncology,” said Dr. David Hallet, Chief Operating Officer of Exscientia. “To meet this expanded growth, we have added more than 100 employees to-date in 2021 and are excited to continue this growth as we seek to add more world-class scientists and technologists to our team.”
Exscientia is a global company, headquartered in Oxford, UK with sites in Miami (FL, US), Vienna (Austria), Dundee (Scotland, UK) and Osaka (Japan). The company currently has over 170 people, roughly split between technologists and drug discovery scientists, with a united goal to find smarter and faster ways to discover and develop new drugs.
ENDS
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Vienna, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005441/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis
EMVCo Requests Feedback on Framework for Secure, Interoperable and Scalable Card-Based Agentic Payments1.9.2026 11:00:00 CEST | Press release
EMVCo – the technical body that creates and manages EMV® Specifications and programmes – has released a draft framework to help promote secure, interoperable and scalable card-based agentic payments. The framework provides a foundation for further industry engagement and potential specification development, with all interested stakeholders encouraged to provide their feedback on EMV® Agentic Payments – Framework for Specificationsby Wednesday 30 September. A key focus across the agentic commerce ecosystem is how to establish intent and determine that a consumer delegated authority to an AI agent to make a purchase on their behalf. Following industry input, EMVCo has focused on card-based agentic payment scenarios where intent needs to be managed over time, such as recurring purchases, cumulative budgets and post-transaction activities. These scenarios may require access to a shared intent ‘state’ that persists across multiple participants and their interactions. EMVCo has identified an
ChargePoint Accelerates European Growth Strategy with Appointment of John Saffrett as EVP and Managing Director, Europe1.9.2026 11:00:00 CEST | Press release
Saffrett brings more than 25 years of leadership experience in global mobility, fleet management, and digital transformationAppointment signals ChargePoint's commitment to accelerating European growth as the company targets increasing its European market and revenue share ChargePoint (NYSE: CHPT), a global leader in intelligent electrification and e-mobility, today announced the appointment of John Saffrett as Executive Vice President and Managing Director, Europe. In this role, Saffrett will be responsible for driving ChargePoint's growth strategy across European markets, overseeing sales, customer relationships, partnerships, and market expansion across the continent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901888806/en/ ChargePoint's EVP and Managing Director John Saffrett He has served as a member of the company’s Advisory Council since March 2026 and is a seasoned global mobility executive with more than 25 ye
Club Vita Launches German VitaCurves Model as Pension Risk Transfer Market Gathers Momentum1.9.2026 10:00:00 CEST | Press release
Address-based longevity model expands Club Vita's global suite of analytics to cover the UK, US, Canada, Netherlands and Germany Club Vita, an international leader in longevity data analytics, has launched a German calibration of its popular address-based longevity model, VitaCurves, further expanding its international footprint and supporting the growing pension risk transfer (PRT) market in Germany. The launch marks another milestone in Club Vita's international expansion and extends its suite of address-based mortality models, which already provides mortality insights in the UK, United States, Canada and the Netherlands. The German VitaCurvesDEU model is already being used by a leading insurer, helping to provide a more granular understanding of longevity risk across pension and insurance portfolios. VitaCurves uses granular location-based and socio-economic data to identify differences in mortality patterns between sub-populations, enabling insurers, pension funds and other stakeho
JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”1.9.2026 09:30:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the benchtop scanning electron microscope (SEM) “JCM-7000Plus” and will begin sales on September 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825564112/en/ JCM-7000Plus NeoScope™ [Development Background] Benchtop scanning electron microscopes are increasingly used in fields including electrical and electronics, automotive and machinery, steel and metals, chemical and pharmaceuticals. They are utilized not only in research and development but also in manufacturing-related applications, such as quality control and product inspection. In addition, they are adopted in educational settings at middle and high schools as well as universities. Given these diverse applications, there is growing demand for improved operational efficiency, simpler and more automated operation, and enhanced observation, analysis, and measurement performance. To meet these needs, we have e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom